Driven by innovation, Keymed has the capabilities of entire-industry-chain from drug discovery, development, manufacturing to commercialization.
滚
动
查
看
更
多
Keymed Biosciences Inc.(Stock Code: 02162 HK) focuses on the urgent unmet clinical needs, and is committed to providing high-quality, affordable, innovative therapies for patients in China and overseas.
Driven by innovation, Keymed has the capabilities of entire-industry-chain from drug discovery, development, manufacturing to commercialization.
Powered by efficient fully integrated in-house R&D capabilities, Keymed has established an industry-leading innovation engine to accelerate the development of novel treatments.
Keymed has built a diversified and world-competitive pipeline in the fields of auto-immune diseases and oncology. So far, the Company has over 30 in house-developed Class I novel drugs in the pipeline, 10 of which are in clinical development at different stages. Each of the drug candidates is among the first three domestically developed for its targets/in its class to have obtained IND approval in China and/or the U.S.
To support the continuous improvement of R&D capabilities and the demand for large-scale commercial manufacture, Keymed's high-standard manufacturing campus located in Tianfu International Bio-town, Chengdu is under construction, in a site occupying 75,333 square meters. After completion, it can provide a robust manufacturing capacity over 70,000 liters, which can satisfy commercial production of 5-15 antibodies. The Manufacturing Campus Phase I Project finished construction and started operation by the end of 2022. The Company has a total of 18,600L capacity, with all the facilities are built and designed in compliance with the cGMP requirements of NMPA and FDA.
We are devoted to becoming a global leading biopharmaceutical company with next-generation therapeutics addressing the urgent unmet clinical needs.
With the mission of “continuous pursuit of innovation and excellence”, we are dedicated to bringing cost-effective medicines to patients globally.
Following patient - oriented principle, we are committed to pursuing higher standards of social value output and bringing curing hope to patients worldwide.
Led by the inventor of the first PD-1 antibody drugs that were developed and approved in the world and China, the core leadership team is composed of top-notch experts in the biopharmaceutical industry, with extensive experience in ground-breaking product development and leadership.
Founded in 2016, Keymed is headquartered in Chengdu and expands footprints across China in Beijing, Shanghai, Wuhan, Nanjing, Guangzhou and Jinan, with 1000 employees currently. Keymed was listed on the Main Board of the Hong Kong Stock Exchange under the stock code “2162”in 2021.